Browse the corpus

Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation, predominately affecting the myocardium. Approximately 25% of patients with systemic evidence of sarcoidosis have cardiac disease involvement. Diagnosing cardiac sarcoidosis is often challenging as the clinical presentation is variable. Patients frequently present with symptoms of heart failure, conduction abnormalities, ventricular arrhythmias, or sudden cardiac death, all of which can be secondary to numerous disease processes. Additionally, there is no single diagnostic test for sarcoidosis, and while endomyocardial biopsy has a high specificity for cardiac sarcoidosis, it is invasive and insensitive. Cardiac sarcoidosis is a rare condition with a poor prognosis. The left ventricular ejection fraction is the most important predictor of mortality in cardiac sarcoidosis. The available treatments for cardiac sarcoidosis are nonspecific and may cause adverse systemic effects. However, early diagnosis and intervention can improve outcomes for patients with this uncommon infiltrative cardiomyopathy. This activity for healthcare professionals reviews the etiology, epidemiology, pathophysiology, symptomatology, diagnostic strategies, and management recommendations for patients with cardiac sarcoidosis and highlights the critical role of the interprofessional team in the management of this cardiac disorder. Objectives: Identify patients who may have cardiac sarcoidosis as suggested by their clinical history. Compare and contrast the efficacy, risks, and benefits of the diagnostic modalities commonly employed for patients with possible cardiac sarcoidosis. Select the most appropriate therapeutic intervention for a patient with cardiac sarcoidosis by applying evidence-based guidelines. Develop and implement effective interprofessional team strategies to improve outcomes for patients with cardiac sarcoidosis. Access free multiple choice questions on this topic.

Cardiac sarcoidosis refers to myocardial involvement occurring either as part of systemic sarcoidosis or as isolated cardiac disease. Sarcoidosis is a multisystem granulomatous disease characterized by noncaseating granulomas in affected tissues.[1] Based on imaging and autopsy findings, cardiac sarcoidosis occurs in approximately 25% of patients with sarcoidosis. Cardiac sarcoidosis is a rare condition with a generally poor prognosis.[2] The diagnosis of cardiac sarcoidosis is often difficult. Sarcoidosis is sometimes considered a diagnosis of exclusion because there is no single diagnostic laboratory, radiologic, or other test. The clinical presentation of sarcoidosis, generally and cardiac sarcoidosis particularly, is highly variable. Cardiac sarcoidosis may present with symptoms of heart failure, sudden cardiac death, ventricular arrhythmia, myocardial infarction, or atrioventricular (AV) block; the most common presentations are conduction system disorders and heart failure.[3] Systemic clinical manifestations of sarcoidosis include signs and symptoms of other organ involvement, such as ocular, neurological, and cutaneous sarcoid.[4] Approximately 25% of patients have isolated cardiac sarcoidosis without systemic involvement, and it is debatable if the prognosis differs from systemic sarcoidosis with cardiac manifestations.[1][5] The most important prognostic indicator in patients with cardiac sarcoidosis is left ventricle ejection fraction (LVEF). Endomyocardial biopsy, an invasive procedure, has a low diagnostic yield due to the patchy involvement of the myocardium. Therefore, advanced imaging studies are employed to enhance the accuracy of diagnosis, particularly in patients without extracardiac manifestations of sarcoidosis.

Cardiac sarcoidosis is likely the result of various environmental, genetic, and immune dysregulation factors. It has been postulated that sarcoidosis may result from an exaggerated immune response to microorganisms and tissue antigens, resulting in chronic granulomatous inflammation, even without an infectious agent.[6] Approximately 5% to 16% of patients with sarcoidosis have a family history of the disease; a correlation between monozygotic twins suggests a genetic component.[7] Certain genes have also been associated with sarcoidosis, including class II MHC HLA-DR3.[2] Environmental factors and the resultant immune response are considered pathogenic mechanisms for cardiac sarcoidosis. Certain environmental and occupational exposures may predispose to sarcoidosis, such as agricultural workers, firefighters, and those exposed to insecticides and microbial bioaerosols in mold. Sarcoidosis may also be more common following exposure to infectious microorganisms such as Chlamydophila pneumoniae, Propionibacterium, and mycobacteria.[8][9] One such study of 25 patients with sarcoidosis and 25 controls demonstrated mycobacteria in 60% of the sarcoid specimens but none of the controls.[2] Cardiac sarcoidosis is also known to recur in the transplanted organs of patients with sarcoidosis who undergo a heart-lung transplant. Evidence exists of sarcoidosis in a nonsarcoid recipient of a heart transplant from a donor with sarcoidosis; this finding supports the hypothesis that the disease is secondary to an immunological or infectious process.[7][10]

The prevalence of cardiac sarcoidosis in the United States and Europe is 10 to 40 persons per 100,000. The prevalence of cardiac sarcoidosisis higher in Black patients (35.5 per 100,000) than in White patients (10.9 per 100,000). The clinical diagnosis of cardiac sarcoidosis is made in only 5% of patients with sarcoidosis. However, autopsy studies reveal cardiac involvement in at least 25% of patients with extracardiac sarcoidosis. Additionally, cardiac magnetic resonance imaging (CMR) and autopsy studies of patients with sarcoidosis have detected evidence of cardiac sarcoidosis in up to 26% of patients who remained asymptomatic.[11] In the United States, the mean age of diagnosis of cardiac sarcoidosis is 53 years, with a slight preponderance in women (58%).[12] The incidence of sarcoidosis and its associated mortality rate is exceptionally high in Black women; a single study reported a prevalence of 2% in this patient population.[5] The clinical presentation of sarcoidosis seems to differ among ethnic groups. Lupus pernio is more common in Puerto Rican and Black patients, while erythema nodosum is more prevalent in patients of European descent.[2] Although the rates of sarcoidosis are low in Japan, when sarcoidosis is present, cardiac sarcoidosis is a common manifestation. Autopsy and imaging studies in Japan reveal a prevalence of cardiac sarcoidosis approaching 50%.[13] Patients with sarcoidosis from Japan also have a higher incidence of cardiac death than similar patients from other countries.[13]

The natural course of sarcoidosis and cardiac sarcoidosis is unpredictable. Patients demonstrate variable inflammatory responses. Some patients respond with minimal local inflammation, while others respond with extensive inflammation and fibrosis. Sarcoidosis is characterized by significant activation of macrophages and CD4+ T cells. This activation increases the production of tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and the expression of the amyloid A protein.[2] The signature lesions of cardiac sarcoidosis are noncaseating granulomas, particularly within the interventricular septum and inferior left ventricle. While granulomas can be found in epicardial, myocardial, and endocardial tissue, the subepicardium and myocardium are most commonly involved, while the endocardium is typically spared.[5][14] Granulomatous involvement of the interventricular septum explains the propensity for conduction system abnormalities. These dysrhythmias include varying degrees of AV block, bundle branch blocks, ventricular arrhythmias, and supraventricular arrhythmias, of which atrial fibrillation is most common. Sarcoid granulomas may involve the left ventricle and cause dilated cardiomyopathy, mitral valve dysfunction, papillary muscle involvement, and left ventricular aneurysms.[2] Most patients with cardiac sarcoidosis have a reduced ejection fraction, but clinical heart failure is uncommon. In patients with known cardiac sarcoidosis, the 10-year incidence of clinically evident heart failure is 3%; this is twice that of the general population.[5] Right ventricular dysfunction in patients with sarcoidosis is usually a consequence of pulmonary fibrosis, pulmonary hypertension, or left ventricular dysfunction, causing right heart failure; granulomatous infiltration of the right ventricle does occur.[2][15] Isolated Cardiac Sarcoidosis Versus Systemic Sarcoidosis With Cardiac Manifestations

Most patients with cardiac sarcoidosis have a reduced ejection fraction, but clinical heart failure is uncommon. In patients with known cardiac sarcoidosis, the 10-year incidence of clinically evident heart failure is 3%; this is twice that of the general population.[5] Right ventricular dysfunction in patients with sarcoidosis is usually a consequence of pulmonary fibrosis, pulmonary hypertension, or left ventricular dysfunction, causing right heart failure; granulomatous infiltration of the right ventricle does occur.[2][15] Isolated Cardiac Sarcoidosis Versus Systemic Sarcoidosis With Cardiac Manifestations There is evidence that isolated cardiac sarcoidosis, defined as cardiac involvement without systemic signs of sarcoidosis, may confer a different clinical picture and prognosis than systemic sarcoidosis with cardiac involvement. Autopsy and imaging studies estimate that 25% of patients with evidence of cardiac sarcoidosis have isolated cardiac sarcoidosis. Many studies have shown that patients with isolated cardiac sarcoidosis have worse prognoses than patients with systemic sarcoidosis and cardiac involvement. Patients with isolated cardiac sarcoidosis typically present with worse left ventricular function and higher rates of ventricular arrhythmia. However, it is unclear whether these findings relate to the disease process or delayed diagnosis due to a lack of systemic manifestations.[1]

The heart is the third-most common site of involvement in systemic sarcoidosis, following the lungs and lymph nodes. The gross pathological examination of autopsy specimens of patients with cardiac sarcoidosis typically reveals patchy myocardial fibrosis, inconsistent with a specific coronary artery distribution.[14] Cardiac granulomas grossly appear as tan, yellow, or brown nodular masses, measure a few millimeters in greatest diameter, and have well-defined margins. Pericardial and endocardial granulomas appear to be an extension of myocardial involvement. Noncaseating granulomas are the characteristic histopathological finding of endomyocardial cardiac sarcoidosis. Sarcoid granulomas can be differentiated from other granulomas due to their compact appearance, epithelioid cell abundance, confluent fibrosis, and fatty infiltration.[16][17] The granulomas comprise macrophages, epithelial cells, and T lymphocytes.[2] Multinucleated giant cells cluster peripherally in a linear fashion and may have cytoplasmic inclusions such as Schaumann or asteroid bodies.[17]

History The most common presenting symptoms of cardiac sarcoidosis include palpitations, presyncope, and syncope related to various arrhythmias, including AV blocks, atrial fibrillation, or other supraventricular and ventricular tachycardia.[2][18][19] Presyncope and syncope may be indicative of underlying life-threatening arrhythmias, such as high-grade AV block or ventricular tachycardia, which can precipitate sudden cardiac death.[5][20] One small study found AV block as the first manifestation of cardiac sarcoidosis in more than 40% of patients; the second-most common presenting symptom in this study of patients with cardiac sarcoidosis was ventricular tachycardia (28%).[21] Alternatively, arrhythmias can lead to more subtle, chronic symptoms of fatigue, exertional dyspnea, and chest discomfort.[22] The predominant symptomatology of patients with right ventricular dysfunction due to left ventricular dysfunction or pulmonary hypertension from pulmonary sarcoidosis may be dyspnea and lower extremity edema. Patients may present with heart failure symptoms such as exertional dyspnea, orthopnea, or paroxysmal nocturnal dyspnea due to dilated or restrictive cardiomyopathy. Patients can also present with respiratory symptoms due to concomitant pulmonary sarcoidosis. Sarcoidosis can also cause coronary vasculitis, and patients may present with symptoms of myocardial ischemia. Physical Examination The physical examination of a patient may reveal tachycardia, bradycardia, an irregular pulse, pedal edema, or jugular venous distention. A loud second heart sound may indicate pulmonary hypertension. A third or fourth heart sound can indicate left ventricular dysfunction. Systolic or diastolic murmurs at the apex are common in mitral valve involvement.[23] Sarcoidosis usually involves multiple organ systems. Pulmonary symptoms are present in 90% of patients; cutaneous, ocular, and neurological manifestations are also common. Erythema nodosum, lupus pernio, uveitis, cranial nerve palsies, or seizures may be indicative of systemic sarcoidosis.[24]

The diagnosis of cardiac sarcoidosis can be histological or clinical. A definite diagnosis of cardiac sarcoidosis can be made with histological evidence of myocardial noncaseating granulomas in tissue obtained via endomyocardial biopsy in the absence of another identified noncaseating granulomatous disease. However, endomyocardial biopsy has a 25% to 36% sensitivity for cardiac sarcoidosis due to patchy involvement of the myocardium. The diagnostic sensitivity of endomyocardial biopsy can be increased to approximately 50% using electrophysiologic mapping.[2] Electrocardiography Electrocardiography (ECG) can identify rhythm abnormalities. However, when patients present with palpitations as the only symptoms, ambulatory rhythm monitoring is superior at identifying transient AV blocks and ventricular tachycardia. The diagnostic yield can be low; less than 10% of patients with asymptomatic cardiac sarcoidosis have an abnormal ECG.[2][25] Echocardiography Echocardiography in patients with cardiac sarcoidosis may reveal thinning of the basal septum, akinetic and dyskinetic regional wall motion abnormalities not in a coronary artery distribution, left ventricular systolic dysfunction, and left ventricular dilation with or without aneurysm.[26] However, echocardiography is an insensitive tool to detect the early stages of the disease, and patients with cardiac sarcoidosis can have a normal echocardiogram. Cardiac Magnetic Resonance Imaging Cardiac magnetic resonance imaging (CMR) provides valuable information about structural cardiac abnormalities. Wall thinning, aneurysms, and chamber dilation are commonly seen in patients with cardiac sarcoidosis.[2] Barring contraindications, gadolinium administration is recommended. Late gadolinium enhancement is a critical diagnostic tool in patients with cardiac sarcoidosis that usually indicates myocardial fibrosis but can also indicate edema. Enhancement is primarily seen in the midseptum and left ventricular subepicardium and myocardium, but not the endocardium. Late gadolinium enhancement is an especially poor prognostic indicator.[2] The sensitivity of CMR for detecting cardiac sarcoidosis is 75% to 100%, and the specificity is 76% to 100%.[27] Fluorodeoxyglucose F 18 Positron Emission Tomography

Cardiac magnetic resonance imaging (CMR) provides valuable information about structural cardiac abnormalities. Wall thinning, aneurysms, and chamber dilation are commonly seen in patients with cardiac sarcoidosis.[2] Barring contraindications, gadolinium administration is recommended. Late gadolinium enhancement is a critical diagnostic tool in patients with cardiac sarcoidosis that usually indicates myocardial fibrosis but can also indicate edema. Enhancement is primarily seen in the midseptum and left ventricular subepicardium and myocardium, but not the endocardium. Late gadolinium enhancement is an especially poor prognostic indicator.[2] The sensitivity of CMR for detecting cardiac sarcoidosis is 75% to 100%, and the specificity is 76% to 100%.[27] Fluorodeoxyglucose F 18 Positron Emission Tomography Fluorodeoxyglucose F 18 positron emission tomography (FDG-PET) is a functional study employing labeled FDG as a surrogate for glucose. Inflammatory cells have a very high metabolic rate; a positive FDG-PET correlates with inflammation. However, myocardial glucose uptake must be suppressed to highlight the inflammatory cells.[28] Suppression is achieved by fasting before the test, consuming a low-carbohydrate and high-fat diet the day before the fast, avoiding exercise during the fast, an altered insulin regimen for people with diabetes the day before the test, and avoiding peritoneal dialysis the day before the test.[29] FDG-PET is staged with cardiac and whole-body imaging and may identify high-yield biopsy sites with active inflammation. FDG uptake in cardiac sarcoidosis can be focal, diffuse, or patchy, and with or without perfusion abnormalities, depending on whether there is inflammation or scar formation. FDG uptake can be decreased in coronary artery disease or ischemia. The sensitivity of FDG-PET is estimated at 89% and specificity at 78%.[28] FDG-PET and CMR are often used in combination to add valuable information about active inflammation, extracardiac involvement, and cardiac structural details.[30] These tests can be used individually or together to assess the effectiveness of therapeutic interventions. Endomyocardial Biopsy

FDG-PET is staged with cardiac and whole-body imaging and may identify high-yield biopsy sites with active inflammation. FDG uptake in cardiac sarcoidosis can be focal, diffuse, or patchy, and with or without perfusion abnormalities, depending on whether there is inflammation or scar formation. FDG uptake can be decreased in coronary artery disease or ischemia. The sensitivity of FDG-PET is estimated at 89% and specificity at 78%.[28] FDG-PET and CMR are often used in combination to add valuable information about active inflammation, extracardiac involvement, and cardiac structural details.[30] These tests can be used individually or together to assess the effectiveness of therapeutic interventions. Endomyocardial Biopsy A biopsy showing noncaseating granulomas is the only definitive way to diagnose cardiac sarcoidosis, but the diagnostic yield is low at 25% to 36% due to the patchy and focal nature of the disease. In patients with extracardiac manifestations of sarcoidosis, an extracardiac biopsy site is preferred due to a higher diagnostic yield and lower rate of complications. If an endomyocardial biopsy is required, FDG-PET or CMR may identify a suitable biopsy site; patients undergoing an electrophysiologic study should be mapped to increase the diagnostic yield of an endomyocardial biopsy. In cases of isolated cardiac sarcoidosis or when an extracardiac biopsy site is nondiagnostic, endomyocardial biopsy may be required to confirm a diagnosis ofcardiac sarcoidosis.[2]

The management of cardiac sarcoidosis aims to slow disease progression, reduce the risk of sudden cardiac death, treat heart failure, and manage arrhythmias. Immunosuppressive Therapy Immunosuppressive therapy is recommended for patients with cardiac sarcoidosis with evidence of cardiac involvement, such as heart block, ventricular arrhythmias, or heart failure, and evidence of active inflammation on histological examination or FDG-PET. The initial therapeutic intervention for cardiac sarcoidosis is immunosuppression with corticosteroids to reduce inflammation and fibrosis; randomized controlled trials investigating the efficacy of corticosteroids have not been performed.[25] Corticosteroids have been reported to reduce the burden of ventricular tachycardia, reverse AV block, and improve LVEF.[31] The goal of corticosteroid immunosuppression is early initiation of therapy before the LVEF decreases and to reduce corticosteroid exposure. A Finnish study of 110 patients, 93% of whom received immunosuppressive therapy, revealed that cardiac transplant-free survival at 1, 5, and 10 years was 97%, 90%, and 83%, respectively.[32] FDG-PET is employed to assess the response to immunosuppression 3 months after initiating therapy. If FDG-PET performed after 3 months of treatment reveals reduced uptake, the corticosteroids may be tapered to complete a 12-month course of therapy. The Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT) is currently being conducted to compare methotrexate with standard- and low-dose prednisone for the initial treatment of cardiac sarcoidosis. Corticosteroid-sparing agents are regularly used in conjunction with corticosteroids to minimize steroid exposure. While no consensus guidelines exist, many clinicians use methotrexate or mycophenolate mofetil with steroids or in patients who appear to be steroid-resistant. Other therapeutic agents used include azathioprine, cyclophosphamide, and leflunomide.[5] Immunologic therapies such as infliximab, adalimumab, and rituximab are considered third- or fourth-line agents in treating cardiac sarcoidosis because of potential complications. Managing Dysrhythmias in Cardiac Sarcoidosis

Corticosteroid-sparing agents are regularly used in conjunction with corticosteroids to minimize steroid exposure. While no consensus guidelines exist, many clinicians use methotrexate or mycophenolate mofetil with steroids or in patients who appear to be steroid-resistant. Other therapeutic agents used include azathioprine, cyclophosphamide, and leflunomide.[5] Immunologic therapies such as infliximab, adalimumab, and rituximab are considered third- or fourth-line agents in treating cardiac sarcoidosis because of potential complications. Managing Dysrhythmias in Cardiac Sarcoidosis When managing conduction abnormalities in patients withcardiac sarcoidosis, it is recommended to follow the 2012 ACCF/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Pacemaker implantation may be helpful in patients with cardiac sarcoidosis and a reversible conduction block. An implantable cardioverter-defibrillator (ICD) may be an option for those requiring permanent pacing. The guidelines suggest immunosuppression can be useful in patients with cardiac sarcoidosis and Mobitz type II or third-degree AV block.[33] Anticoagulation is recommended for patients with cardiac sarcoidosis and atrial fibrillation, as guided by the CHA2DS2-VASc score. A therapeutic electrophysiology study may be performed in patients with cardiac sarcoidosis and atrial arrhythmias, except for atrial fibrillation. Class I antiarrhythmic medications carry a class III indication in patients with cardiac sarcoidosis and arrhythmias.[33] The consensus guidelines suggest that an FDG-PET is useful for identifying inflamed myocardium in patients with cardiac sarcoidosis. Furthermore, immunosuppressive therapy can be useful in cardiac sarcoidosis patients with unustained ventricular ectopy or sustained ventricular arrhythmias. Antiarrhythmic medications and catheter ablation are recommended for ventricular tachycardia unresponsive to immunosuppression. The initial therapeutic strategy for patients with cardiac sarcoidosis and ventricular tachycardia is corticosteroids and amiodarone; catheter ablation is reserved for patients refractory to medical therapy.[33]

The consensus guidelines suggest that an FDG-PET is useful for identifying inflamed myocardium in patients with cardiac sarcoidosis. Furthermore, immunosuppressive therapy can be useful in cardiac sarcoidosis patients with unustained ventricular ectopy or sustained ventricular arrhythmias. Antiarrhythmic medications and catheter ablation are recommended for ventricular tachycardia unresponsive to immunosuppression. The initial therapeutic strategy for patients with cardiac sarcoidosis and ventricular tachycardia is corticosteroids and amiodarone; catheter ablation is reserved for patients refractory to medical therapy.[33] An ICD is recommended for patients with cardiac sarcoidosis and a spontaneous sustained ventricular arrhythmia that includes prior cardiac arrest or those with LVEF less than 35% despite medical therapy and immunosuppression. ICD therapy is useful in patients with cardiac sarcoidosis with a pacer indication, unexplained syncope or presyncope of likely arrhythmic etiology, or inducible sustained ventricular arrhythmia. ICD therapy may be considered in patients with LVEF of 36% to 49% and RV ejection fraction less than 40% on optimal medical therapy and immunosuppression. ICD therapy is not recommended in patients with incessant ventricular arrhythmias or New York Heart Association class IV heart failure. Additionally, ICD therapy is not indicated in patients with no history of arrhythmia or syncope, no pacing indication, normal LV/RV function, absent late gadolinium enhancement during CMR, or a negative electrophysiologic study.[33]

Cardiac sarcoidosis is a challenging diagnosis. Myocarditis can be especially difficult to distinguish from cardiac sarcoidosis due to similar clinical presentations, including ventricular arrhythmias, heart failure, late gadolinium enhancement on CMR, and abnormal uptake on FDG-PET. Viral myocarditis may or may not be preceded by a viral prodrome, and giant cell myocarditis usually has a more fulminant course.[34] An endomyocardial biopsy may be needed to distinguish these from sarcoidosis. Cardiomyopathies, particularly arrhythmogenic right ventricular cardiomyopathy (ARVC), are another condition that can present with findings very similar to cardiac sarcoidosis.[35] Ventricular arrhythmias are common in both conditions; AV block and heart failure symptoms are more common in cardiac sarcoidosis.[35][36] Ventricular septal late gadolinium enhancement is usually absent in patients with ARVC, while intramyocardial fat infiltration is more likely.[37] Extracardiac manifestations consistent with sarcoidosis are also more likely to favor cardiac sarcoidosis. Late gadolinium enhancement on CMR is observed in many pathologic conditions, including myocardial infarction, cardiac amyloidosis, hypertrophic cardiomyopathy, Fabry disease, and hereditary hemochromatosis. An enhancement pattern within the distribution of coronary artery supply can help distinguish cardiac sarcoidosis from scarring secondary to prior myocardial infarction and cardiac sarcoidosis. Hereditary hemochromatosis can present with arrhythmias and heart failure but is associated with skin hyperpigmentation, diabetes, and evidence of reduced T2-weighted times on CMR.[38] The myocardial granulomas characteristic of cardiac sarcoidosis can also be seen in tuberculosis, fungal infections, systemic vasculitis, and immunodeficiencies.[39] However, these conditions have significantly different clinical presentations, which can be differentiated by historical and physical examination findings in addition to diagnostic testing.

Patients with systemic sarcoidosis and cardiac sarcoidosis have a worse prognosis than patients with extrapulmonary sarcoidosis without cardiac involvement. A history of sustained ventricular tachycardia, an increased left ventricular end-diastolic diameter, and an increased NYHA class are independent predictors of mortality in patients with cardiac sarcoidosis.[32] Heart failure as a clinical manifestation and reduced LVEF carry an especially poor prognosis with a reported 10-year survival of 19 % to 53% in the absence of cardiac transplant.[40] Cardiac sarcoidosis carries a poor prognosis compared to other forms of sarcoidosis.[18] It is unclear whether silent cardiac sarcoidosis has a better prognosis than cardiac sarcoidosis with clinical manifestations. However, patients with asymptomatic cardiac sarcoidosis and a benign course might initially present with sudden cardiac arrest. Patients with cardiac sarcoidosis and evidence of late gadolinium enhancement on CMR or abnormal uptake and perfusion defects on FDG-PET have an increased risk of VT and cardiovascular death.[41] Right ventricular dysfunction and RV late gadolinium enhancement may also have prognostic implications. Among 260 biopsy-proven patients with cardiac sarcoidosis, RV systolic function was independently associated with all-cause mortality. In contrast, right ventricular late gadolinium enhancement was associated with sudden cardiac death and ventricular arrhythmia.[42]

If untreated, cardiac sarcoidosisusually leads to dilated cardiomyopathy and an increased risk of ventricular arrhythmias. Untreated or refractory pulmonary sarcoidosis that progresses to pulmonary fibrosis can lead to right heart failure.[15][2] Sudden cardiac death is the most feared complication of cardiac sarcoidosis, warranting risk stratification and evaluation for an ICD.[20] The following complications are also commonly encountered in patients with cardiac sarcoidosis: Left and right heart failure Cardiomyopathy with or without heart failure Ventricular arrhythmia Bradyarrhythmias, such as variable degrees of atrioventricular block, including third-degree heart block Sudden cardiac death Atrial tachycardia, including atrial fibrillation Pulmonary hypertension with subsequent right heart failure Coronary vasculitis and myocardial ischemia.

Cardiac sarcoidosis is a determinant of prognosis in patients with systemic sarcoidosis. Cardiac sarcoidosis portends an increased risk of ventricular arrhythmias and sudden cardiac death. Patients with cardiac sarcoidosis should be aware of the progressive nature of the disease and the need for repeat evaluation and imaging to guide timely therapy. Patients can have symptoms of multisystem involvement and might need to see an organ-specific specialist for appropriate management. Patients with this condition need to initiate immunosuppression promptly to decrease the progression of the disease process in the heart.

Cardiac sarcoidosis is best managed by an interprofessional approach to enhance the chances of diagnosing cardiac sarcoidosis and recognizing coexisting extracardiac manifestations of sarcoidosis. Cardiac sarcoidosisis a frequently missed diagnosis, given its rarity and the high index of suspicion needed to make the diagnosis. The combined effort of advanced imaging specialists, electrophysiologists, and interventional cardiologists is often required to diagnose cardiac sarcoidosis. Early diagnosis and immunosuppression initiation are clearly beneficial in reducing disease progression.[31] A holistic approach to management is recommended, with care coordination between primary care clinicians, cardiologists, pulmonologists, and immunologists. Electrophysiology support can help risk-stratify patients who need device implantation to prevent sudden cardiac death. Patient care is enhanced by involving advanced heart failure specialists to identify those who may benefit from referral for advanced heart failure therapies.[32]